Slater Technology Fund
Description: The agreement includes two clinical stage molecules for schizophrenia and movement disorders and MIJ821, a clinical stage molecule previously licensed exclusively by Novartis for addressing treatment-resistant depression.The deal builds on Novartis expertise in neuroscience and advances the company’s development of potential neuropsychiatric medicines. Basel, December 17, 2020 — Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts based neuroscience company. The acqui
novartis (80) scientific research (78) scientific discoveries (7) reimagine medicine (3)
Learn about how Novartis is organized and our strategy, vision and mission. Meet our people and read about our commitments to diversity, equity and inclusion. Explore our history which goes back more than 250 years.
Patients and Caregivers
Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.
Slater Technology Fund